Hämostaseologische Therapie mit Prostaglandinen aus pharmakologischer Sicht

• LITERATUR

• 1 Aren C, Feddersen K, Radegran K. Effects of prostacyclin infusion on platelet activation and postoperative blood loss in coronary bypass. Ann Thorac Surg 1983; 36: 49-54.
• 2 Aren C, Feddersen K, Radegran K. Effects of prostacyclin infusion on platelets and hemodynamics in coronary bypass surgery. Thorac Cardiovasc Surg 1984; 32: 81-4.
• 3 Berglund U, von Scheck H, Wallentin L. Effects of ticlopidine on platelet function in men with stable angina pectoris. Thromb Haemost 1985; 54: 808-12.
• 4 Bunce I, Ward M, Solomon E, Cowen A. Platelet function in patients receiving enprostil. Am J Med 1986; 81: 85-8.
• 5 Bunting S, O’Grady J, Fabiani J N, Terrier E, Moncada S, Vane J R, Dubost C. Cardiopulmonary bypass in man: effects of prostacyclin. In: Clinical Pharmacology of Prostacyclin. Lewis P J, O’Grady J. (eds). New York: Raven Press; 1981: 181.
• 6 Cizmeci G. In vivo effects of defibrotide on platelet c-AMP and blood prostanoid levels. Haemostasis 1986; 16 (Suppl. 01) 31-5.
• 7 Coppe D, Sobel M, Seamans L, Levine F, Salzman E. Preservation of platelet function and number by prostacyclin during cardiopulmonary bypass. J Thorac Cardiovasc Surg 1981; 81: 274.
• 8 Crutchley D J, Conanan L B, Maynard J R. Stimulation of fibrinolytic activity in human skin fibroblasts by prostaglandins E₁, E₂ and I₂ . J Pharmacol Exp Ther 1982; 222: 544-9.
• 9 Darius H, Hossmann V, Schrör K. Antiplatelet effects of intravenous iloprost in patients with peripheral arterial obliterative disease. Klin Wochenschr 1986; 64: 545-51.
• 10 Davi G, Cannizzaro S, Giubilato A, Novo S, Mattina A, Strano A. Enhanced platelet sensitivity to prostacyclin after isosorbide-5-mononitrate in patients with stable angina pectoris. Z Kardiol 1986; 75 (Suppl. 03) 80-2.
• 11 Dembinska-Kiec A, Kostka-Trabka E, Zumbda A, Byrska-Danek A, Bieron K, Grodzinska L, Kedzior A, Zelazny T. Effect of prostacyclin (PGI₂) on platelets and fibrinolytic activity in patients with arteriosclerosis obliterans. Pharmacol Res Commun 1982; 14: 485-98.
• 12 Dembinska-Kiec A, Zmuda A, Grodzinska L, Bieron K, Basista M, Kedzor A, Kostka-Trabka E, Telesz E, Zelazny T. Increased platelet activity after termination of prostacyclin infusion into man. Prostaglandins 1981; 21: 827-32.
• 13 Ditter H, Heinrich D, Matthias F R, Sellmann-Richter R, Wagner W L, Herlein F W. Effects of prostacyclin during cardiopulmonary bypass in men on plasma levels of beta-thromboglobulin, platelet factor 4, thromboxane B2, 6-keto-prostaglandin Fl_α and heparin. Thromb Res 1983; 32: 393-408.
• 14 Eika C. Inhibition of thrombin induced aggregation of human platelets by heparin. Scand J Haematol 1971; 08: 216-22.
• 15 Eldor A, Weksler B B. Heparin and dextrane sulfate antagonize PGI₂ inhibition of platelet, aggregation. Thromb Res 1979; 16: 617-28.
• 16 Fisher C A, Reiser H J, Addonizzio P. Preliminary comparison of the effects of iloprost, prostacyclin (PGI₂) and prostaglandin E₁ on human platelet function. In: Prostacyclin and its Stable Analog Iloprost. Gryglewski R J, Stock G. (Eds). Berlin: Springer; 1987: 65-8.
• 17 Fitscha P, Kaliman J, Sinzinger H. Gamma-camera imaging after autologous human platelet labeling with ¹¹¹In-oxine-sulfate: a key for assessing the efficacy of prostacyclin treatment in active atherosclerosis?. In: Prostaglandins and Other Eicosanoids in the Cardiovascular System. Schrör K. (Ed). Basel: Karger; 1985: 352-7.
• 18 Foegh M L, Alijani M R, Helfrich G B, Ramwell P W. Eicosanoids and organ transplantation. Ann Clin Res 1984; 16: 318-23.
• 19 Foegh M L, Rowles J R, Khirbadi B S, Ramwell P W. Allograft survival with iloprost. In: Prostacyclin and its Stable Analog Iloprost. Gryglewski R J, Stock G. (Eds). Berlin: Springer; 1987: 243-6.
• 20 George J N, Käser-Glanzmann R, Kallabora M, Liischer E F. Adenosine 3’5-cyclic monophosphate (cAMP) stimulation of active calcium transport by a membrane fraction from human platelets: a possible controlling mechanism of platelet function. Blood 1976; 48: 1007.
• 21 Gorman R R, Bunting S, Miller O V. Modulation of human platelet adenylate cyclase by prostacyclin (PGX).. Prostaglandins 1977; 13: 377.
• 22 Gimson A, Braude S, Mellon P, Canalese J, Williams R, Weston M. Prostacyclin to prevent platelet activation during charcoal haemoperfusion in fulminant hepatic failure. Lancet 1982; I: 173.
• 23 Gimson A, Braude S, Mellon P, Canalese J, Williams R. Earlier charcoal haemoperfusion in fulminant hepatic failure. Lancet 1982; II: 681-3.
• 24 Gryglewski R J, Szczeklik A. Prostacyclin in vascular pathology-therapeutic possibilities. Ann Clin Res 1984; 16: 253-61.
• 25 Heinrich D, Schleussner E, Wagner W L, Sellmann-Richter R, Hehrlein F W. Prostacyclin in aortocoronary bypass surgery: a double-blind, placebo-controlled study. Thromb Res 1983; 32: 409-26.
• 26 Higgs G A, Moncada S, Vane J R. Prostacyclin (PGI₂) inhibits the formation of platelet thrombin induced by adenosine diphosphate (ADP) in vivo. Br J Pharmacol 1977; 61: 137P
• 27 Kloeze J. Relationship between chemical structure and platelet aggregation activity of prostaglandins. Biochim Biophys Acta 1969; 187: 285.
• 28 Kloeze J. Influence of prostaglandins on platelet adhesiveness and platelet aggregation. In: Prostaglandins. Proceedings of the Second Nobel Symposium. Bergström S, Samuelsson B. (Eds). Stockholm: Almqvist und Wiksell; 1966: 241.
• 29 Koshal A, Krausz M M, Utsonomiya T, Hechtman H B, Collins J J, Cohn L H. Preservation of platelets and their function in prolonged cardiopulmonary bypass using prostacyclin. Circulation 1981; 64: 44.
• 30 Leithner C, Sinzinger H, Pohanka E, Schwarz M, Syre G. ¹¹¹Indiummarkierte Thrombozyten in der Diagnostik von akuten Nierentransplantatabstoßungen und zur Observierung der Therapie von Abstoßungsreaktionen mit Prostacyclin. Wien Klin Wochenschr 1984; 96: 112-7.
• 31 Leithner C, Sinzinger H, Schwarz M. Treatment of chronic kidney transplant rejection with prostacyclin – reduction of platelet deposition in the transplant; prolongation of platelet survival and improvement of transplant function. Prostaglandins 1981; 22: 783-8.
• 32 Lewis P J, Dollery C T. Clinical pharmacology and potential of prostacyclin. Br Med Bull 1983; 39: 281-4.
• 33 Lewis R, Schoelkens B A, Beck G. Biological activities of 6-keto-prostaglandin E₁ . Prostaglandins Leukotrienes Med 1984; 16: 303-24.
• 34 Löbel P, Schrör K. Selective stimulation of coronary vascular PGI₂ but not of platelet thromboxane formation by defibrotide in the platelet perfused heart. Naunyn-Schmiedeberg’s Arch Pharmacol 1985; 331: 125-30.
• 35 Longmore D B. Experience with prostacyclin in cardiopulmonary bypass in dog and man. Philos Trans R. Soc Lond (Biol) 1981; 294: 399-412.
• 36 Longmore D, Bennet J, Hoyle P, Smith M, Gregory A, Osivand T, Jones W. Prostacyclin administration during cardiopulmonary bypass in man. Lancet 1981; I: 800-3.
• 37 MacDermot J. Desensitization of prostacyclin responsiveness in platelets. Apparent differences in the mechanism in vitro or in vivo. Biochem Pharmacol 1986; 35: 2645-9.
• 38 Machin S J, Yardumain D A, O’Flynn K, Linch D C. Laboratory investigations of potential hepariniloprost interactions. In: Prostacyclin and its Stable Analog Iloprost. Gryglewski R J, Stock G. (Eds). Berlin: Springer; 1987: 69-79.
• 39 Malpass T W, Hanson S R, Savage B, Hessel E A, Harker L A. Prevention of aquired transient defect in platelet plug formation by infused prostacyclin. Blood 1981; 57: 736.
• 40 Mitchell J R. Prostacyclin – powerful, yes: but is it useful?. Br Med J 1983; 287: 1824-6.
• 41 Noback C, Tinker J, Kaye M, Holocom G, Pluth J. Prostacyclin : a potent vasodilator during anaesthesia and cardiac surgery in man. Circulation 1983; 62 (Suppl III): 111-322.
• 42 Preston F E. Aspirin, prostaglandins, and peripheral gangrene. Am J Med 1983; 74: 55-60.
• 43 Radegran K, Papaconstantinou C. Prostacyclin infusion during cardiopulmonary bypass in man. Thromb Res 1980; 19: 267-70.
• 44 Radegran K, Aren C, Teger-Nilsson A C. Prostacyclin infusion during extracorporeal circulation for coronary bypass. J Thorac Cardiovasc Surg 1982; 83: 205-122.
• 45 Reches A, Eldor A, Salomon Y. Heparin inhibits PGE! sensitive adenylate cyclase and antagonizes PGEi anti aggregating effect in human platelets. J Lab Clin Med 1979; 93: 638.
• 46 Rylance P B, Gordge M P, Ireland H, Lane D A, Weston M J. Haemodialysis with prostacyclin (Epoprostenol) alone. Proc Eur Dial Transplant Assoc Eur Ren Assoc 1985; 21: 281-6.
• 47 Salzman E W, Merill E W. Interaction of blood with artificial surfaces. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Colman R W, Hirsh J, Salzmann E W. (Eds). Philadelphia – Toronto: Lippincott; 1982: 931.
• 48 Schrör K, Ahland B, Darius H, Weiss P. Stimulation of vascular PGI₂ by organic nitrates and its significance for the antianginal effect. Scand J Clin Lab Invest 1984; (Suppl) 173: 33-40.
• 49 Schrör K. Kardiovaskuläre Wirkung von Prostaglandin E₁ (PGE₁)-Mechanismen und ihre mögliche klinische Bedeutung. In: Prostaglandin E₁. Therapie der arteriellen Verschlußkrankheit. Schrey A. (Hrsg). München: Wolf; 1985: S15-32.
• 50 Schrör K, Hecker G. Potent inhibition of superoxide anion generation by PGE₁ and the PGE₁ analog OP-1206 in human PMN’s – unrelated to its antiplatelet PGI₂-like activity. Vasa 1987; (Suppl. 17) 11-6.
• 51 Sinzinger H, Fitscha P. Influence of prostaglandin E₁ on in-vivo accumulation of radiolabelled platelets and LDL on human arteries. Vasa 1987; (Suppl. 17) 5-10.
• 52 Sinzinger H, Reiter S. The intrainfusion platelet rebound during and following PGE₁infusion is faster and more intensive than that with PGI₂ . Prostaglandins Leukotrienes Med 1984; 13: 281-8.
• 53 Sinzinger H, Matejka M, Steurer G, Kaliman J, Ettl K. The interaction between the platelet- derived growth factor (PDGF) and prostaglandin (PG)I₂ is important for atherogenesis. Abstr 6th International Conference on Prostaglandins 1986; 14
• 54 Sinzinger H, Kaliman J, Widhalm K, Pachinger O, Probst P. Value of platelet sensitivity to antiaggregatory prostaglandins (PGE₂, PGE₁ PGD₂) in 50 patients with myocardial infarction and young age. Prostaglandins Med 1981; 07: 125-32.
• 55 Sinzinger H, Horsch A K, Silberbauer K. The behaviour of various platelet function tests during long-term prostacyclin infusion in patients with peripheral vascular disease. Thromb Haemost 1983; 50: 885.
• 56 Sinzinger H, Silberbauer K, Horsch A K, Gall A. Decreased sensitivity of human platelets to PGI₂ during long-term intraarterial prostacyclin infusion in patients with peripheral vascular disease – a rebound phenomenon. Prostaglandins 1981; 21: 49-51.
• 57 Sinzinger H, Silberbauer K, Feigl W, Wagner O, Winter M, Auerswald W. Prostacyclin activity is diminished in different types of morphologically controlled human atherosclerotic lesions. Thromb Haemostas 1979; 42: 803-4.
• 58 Smith D L, Willis A L, Nguyen N, Dave S, Yih R, Nakamura G. Antiatherosclerotic properties of prostacyclins on release of mitogens from platelets and endothelial cells. Excerpta Medica Intern Cong Ser 1986; 696: 453-6.
• 59 Strom T B, Carpenter C B. Prostaglandin as an effective antirejection therapy in rat renal allograft recipients. Transplantation 1983; 35: 279-81.
• 60 Stürzebecher C-S, Losert W. Effects of iloprost on platelet activation in vitro. In: Prostacyclin and its Stable Analog Iloprost. Gryglewski R J, Stock G. (Eds). Berlin: Springer; 1987: 39-46.
• 61 Turney J H, Fewell M R, Williams L C, Parsons V, Westo M J. Platelet protection and heparin sparing with prostacyclin during regular dialysis therapy. Lancet 1980; I: 219.
• 62 van den Dungen J J, Karliczek G F, Brenken U, van der Heide J N, Wildevuur C R. The effect of prostaglandin Ej in patients undergoing clinical cardiopulmonary bypass. Ann Thorac Surg 1983; 35: 406-14.
• 63 Vane J R. Prostacyclin in the cardiovascular system in health and disease. In: Prostaglandins and Other Eicosanoids in the Cardiovascular System. Schrör K. (Ed). Basel: Karger; 1985: 7-38.
• 64 Walker I D, Davidson J F, Faichney A, Wheatley D J, Davidson K G. A double blind study of prostacyclin in cardiopulmonary bypass surgery. Br J Haematol 1981; 49: 415-23.
• 65 Weeks J R, Chandra NSekar, Ducharme D W. Relative activity of prostaglandins E₁, A₁, E₂ and A₂ on lipolysis, platelet aggregation, smooth muscle and the cardiovascular system. J Pharm Pharmacol 1969; 21: 103.
• 66 Yardumian D A, Mackie I J, Brennan E C, Bull H, Machin S J. Platelet function studies during and after infusions of ZK 36374, a stable prostacyclin analogue, to healthy volunteers. Haemost 1986; 16: 20-6.
• 67 Zusman R, Rubin R, Cato A, Cochetto D, Crow J, Tolkoff-Rubin N. Haemodialysis using prostacyclin instead of heparin as the sole antithrombotic agent. N Engl J Med 1981; 304: 934-9.